Search - tctmd.com

Displaying 1 - 20 of 28

Sort: Relevancy | Date

ESC Guidelines Update Clarifies Pregnancy Risks and Choices in Women With CVD

News Conference News ESC 2025

ESC Guidelines Update Clarifies Pregnancy Risks and Choices in Women With CVD

September 09, 2025

Vericiguat Misses Mark in Stable, Well-Treated HFrEF Patients: VICTOR

News Conference News ESC 2025

Vericiguat Misses Mark in Stable, Well-Treated HFrEF Patients: VICTOR

Michael O'Riordan

August 31, 2025

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

News Conference News ESC 2025

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

August 30, 2025

Starting SGLT2 inhibitors in the Hospital for Acute HF Gains Support

News Conference News ESC 2025

Starting SGLT2 Inhibitors in the Hospital for Acute HF Gains Support

August 30, 2025

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

CASTLE-HTx: AF Ablation Boosts Outcomes in Advanced Heart Failure

News Conference News ESC 2023

CASTLE-HTx: AF Ablation Boosts Outcomes in Advanced Heart Failure

August 28, 2023

Qiliqiangxin, a Traditional Chinese Medication, Cuts CV Events in HF: QUEST

News ESC 2023

Qiliqiangxin, a Traditional Chinese Medication, Cuts CV Events in HF: QUEST

Michael O'Riordan

August 27, 2023

What’s Going to Be Hot at ESC 2023?

News Opinion Editor's Corner ESC 2023

What’s Going to Be Hot at ESC 2023?

August 15, 2023

New ESC/ERS Pulmonary Hypertension Guidelines Urge Precise Diagnosis, Early Treatment

News Conference News ESC 2022

New ESC/ERS Pulmonary Hypertension Guidelines Urge Precise Diagnosis, Early Treatment

September 01, 2022

DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum

News Conference News ESC 2022

DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum

August 27, 2022

Old Drug Acetazolamide Offers New Tricks in Acute HF: ADVOR

News Conference News ESC 2022

Old Drug Acetazolamide Offers New Tricks in Acute HF: ADVOR

August 27, 2022

EchoNet AI Algorithm Beats Sonographers for Estimating LV Function

News Conference News ESC 2022

EchoNet AI Algorithm Beats Sonographers for Estimating LV Function

August 27, 2022

PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2

News Conference News ESC 2022

PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2

Michael O'Riordan

August 27, 2022

IAMI: Influenza Vaccine Beneficial for Post-MI Patients

News Conference News ESC 2021

IAMI: Influenza Vaccine Beneficial for Post-MI Patients

Michael O'Riordan

August 30, 2021

COVID-19 Blamed for Weaker Research Published by Top-Tier Journals in 2020

News Conference News ESC 2020

COVID-19 Blamed for Weaker Research Published by Top-Tier Journals in 2020

Michael O'Riordan

September 04, 2020

PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF

News Conference News ESC 2020

PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF

August 30, 2020

EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class

News Conference News ESC 2020

EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class

Michael O'Riordan

August 29, 2020

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

News Conference News ESC 2020

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

Michael O'Riordan

August 28, 2020

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

News Conference News ESC 2019

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

Yael L. Maxwell

September 12, 2019

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

News Conference News ESC 2019

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

September 01, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.